Antidepressant News and Research

RSS

Antidepressants are medicines that treat depression. Your doctor can prescribe them for you. They can improve your mood, sleep, appetite and concentration. It may take several weeks for them to help. There are several types of antidepressants. You and your doctor may have to try several before finding what works best for you.

Psilocybin reshapes brain connections through distinct cellular pathways

A new study led by researchers at the University of California, Santa Cruz, reveals how psilocybin, the psychoactive compound in "magic mushrooms," reshapes neural connections in the brain.

22 Oct 2026

Depression profile linked to disrupted sleep and poorer treatment responses

This study uncovers a circadian depression subtype, revealing links between sleep patterns, symptom severity, and antidepressant response in a large cohort.

22 Oct 2026

Accelerated TMS cuts depression treatment time from six weeks to three

Transcranial magnetic stimulation (TMS) has proved to be a very effective non-invasive treatment for people with severe depression who have not had success with medication. But traditional TMS has one significant drawback: time.

21 Oct 2026

Researchers identify new depression subtype linked to the body clock

Research by experts at the University of Sydney has identified a new subtype of depression called "circadian depression".

20 Oct 2026

Residential greenery linked to lower dementia risk in older adults

Urban residents with more greenery within 100 meters of their homes have a lower risk of developing dementia over time.

19 Oct 2026

Ketamine may ease early depressive symptoms after cesarean delivery

Ketamine, a medication used in operating rooms for anesthesia and pain control, may offer another benefit for some new mothers: easing early symptoms of postpartum depression after cesarean delivery (C-section), according to a study presented at the ANESTHESIOLOGY® 2026 annual meeting.

19 Oct 2026

Medical cannabis benefits for insomnia remain uncertain, Cochrane review finds

A new Cochrane review finds that existing evidence is too uncertain to determine whether medical cannabis improves sleep or daytime functioning in people with insomnia.

12 Oct 2026

Screen time was linked to teen anxiety. Then researchers compared twins

A longitudinal study of 21,797 Swedish twins found that heavy interactive screen use during adolescence was associated with more anxiety and depressive symptoms and a higher likelihood of subsequent clinical mental health outcomes. However, these associations weakened substantially when comparing twins with different screen habits, suggesting that shared genetic and environmental factors contribute to the relationship.

12 Oct 2026

Long-term opioid use does not improve chronic back pain outcomes

Taking opioids for years does not seem to improve pain and functioning in people with chronic back pain, according to a new Northwestern University study that compared 70 long-term opioid users to 70 similar patients not taking opioids.

6 Oct 2026

Maternal depression linked to neurodevelopmental disorders in children

Children of mothers with depression had higher rates of certain neurodevelopmental disorders regardless of whether they were exposed to antidepressants in the womb, reports a new study led by Saraid McIlvride of the University of Glasgow, UK, published September 29th in the open access journal PLOS Medicine.

29 Sep 2026

Could age help explain why psychedelic studies reach different conclusions?

A cross-sectional study of 1,088 adults found that lifetime classic psychedelic use was associated with lower current anxiety and depression symptoms among younger adults, but these associations weakened with age. Mystical experiences may partly explain the age-related pattern, although the observational design cannot establish that psychedelic use caused the mental health differences.

27 Sep 2026

The heart effects of antidepressants may depend as much on the patient as the drug

Antidepressants differed in their effects on QTc, with amitriptyline and escitalopram producing small average increases, and the magnitude of changes varying according to individual patient characteristics. The trials did not detect an increase in early major cardiovascular events or non-suicidal sudden death, but they were not large or long enough to rule out rare or later cardiovascular events.

24 Sep 2026

Add-on drug lumateperone boosts sexual function in patients with depression

Patients with major depressive disorder (MDD) and an inadequate response to standard antidepressants who received an add- on treatment with the drug lumateperone saw significantly improved sexual function, found a new study led by a University of Virginia School of Medicine researcher.

15 Sep 2026

A study of ayahuasca users found a mental health pattern researchers cannot yet explain

In a cross-sectional study of 808 Brazilian adults planning to attend ayahuasca ceremonies, greater prior experience with the brew was associated with lower depression, anxiety, and stress scores, as well as higher spiritual well-being and stronger metaphysical beliefs. Because the study was observational and relied on self-reported data, it cannot show that ayahuasca caused these differences.

13 Sep 2026

GLP-1 drugs looked promising for depression. The evidence tells a more complicated story

A systematic review of 43 studies found highly heterogeneous results for GLP-1 receptor agonists across animal models and human research assessing depression-, anxiety-, and stress-related outcomes. No study directly tested these drugs as a treatment for PTSD, and the available evidence does not currently support their use for depression or PTSD, although people with metabolic dysfunction may warrant further investigation.

7 Sep 2026

GLP-1 drugs appear psychiatrically safe, but one finding still raises questions

A systematic review of 11 observational studies representing more than 4.9 million patients found that GLP-1 receptor agonists were generally associated with neutral or potentially protective psychiatric outcomes, although one obesity-focused cohort reported increased risks of depression, anxiety, and suicidal behavior. Direct evidence for antidepressant effects remains limited, with only one cross-sectional study using validated mood scales and no randomized trials in the final synthesis, meaning causality cannot be established

6 Sep 2026

Single-dose psilocybin shows promise for treatment-resistant depression in NHS trial

A single 25-mg dose of psilocybin with psychological support was feasible to deliver within an NHS setting and produced large preliminary reductions in depressive symptoms among adults with treatment-resistant depression. The Phase 2 feasibility trial also found the treatment was generally well tolerated, although functional unblinding and expectancy effects mean larger, longer efficacy studies are needed.

10 Aug 2026

High-resolution scans reveal how depression affects hippocampal subfields

Researchers from the USC Mark and Mary Stevens Neuroimaging and Informatics Institute (Stevens INI) at the Keck School of Medicine of USC have found that depression is associated with smaller volume in a specific part of the hippocampus, a brain region essential for learning and memory.

6 Aug 2026

Brain immune cells drive recovery from ketamine anesthesia in females

During ketamine anesthesia, the brain's nerve cells fall silent-as consciousness returns, they begin to reconnect.

31 Jul 2026

Research identifies common neuroimmune signatures in rapid-acting antidepressants

In a new study, researchers from The University of Texas MD Anderson Cancer Center have uncovered insights that may help explain how rapid-acting antidepressants, such as ketamine and psychedelics, can reduce symptoms in difficult-to-treat depression.

30 Jul 2026